Delcath(US:DCTH)2026-02-26 14:15FDA Approval and Market Introduction - The HEPZATO KIT was approved by the FDA on August 14, 2023, for liver-directed treatment of adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver[25]. - HEPZATO KIT received FDA approval in August 2023 for adult uveal melanoma patients with unresectable liver metastases, allowing for up to ten treatments in commercial settings[51]. - The first commercial use of HEPZATO for treating metastatic hepatic dominant uveal melanoma occurred in January 2024[25]. - HEPZATO KIT became commercially available in January 2024, with 32 sites accepting referrals and 25 active sites as of December 31, 2025[66][68]. Market Opportunity and Addressable Market - The total addressable market for liver cancer (primary and metastatic) in the United States is estimated to be approximately 200,000 cases per year, with a market value exceeding $1.0 billion[31]. - An estimated 800 patients with uveal melanoma liver metastases in the United States and 1,200 in Europe may be eligible for treatment with HEPZATO or CHEMOSAT annually, representing a market of approximately $600 million per year[34]. - Approximately 98,000 colorectal cancer patients in the United States, the United Kingdom, and the European Union could be candidates for treatment with HEPZATO and CHEMOSAT[36]. - The annual addressable market for breast cancer patients with hepatic involvement in the United States and the European Union is estimated to be around 6,000 patients, with an additional 10,000 patients potentially benefiting from treatment in the palliative setting[39]. - Approximately 65,000 hepatocellular carcinoma patients annually in the United States and Europe could be candidates for treatments with HEPZATO and CHEMOSAT, representing the largest segment of the primary liver cancer market[45]. - The estimated number of neuroendocrine tumor patients in the United States, the United Kingdom, and the European Union who could be candidates for treatment with HEPZATO and CHEMOSAT is approximately 7,500 annually[41]. - The estimated total addressable market (TAM) for liver-dominant metastatic colorectal cancer (mCRC) is between 6,000 and 10,000 patients annually in the United States[62]. Clinical Trials and Efficacy - The FOCUS Trial reported an overall response rate (ORR) of 36.3%, significantly higher than the historical control group's ORR of 5.5%, with 7.7% of patients achieving a complete response[52]. - The CHOPIN trial demonstrated an objective response rate of 85.7% and a disease control rate of 100% in patients treated with CHEMOSAT combined with immune checkpoint inhibitors[54]. - In the Phase 2 trial of the CHOPIN study, the combination group achieved a one-year progression-free survival rate of 54.7% compared to 15.8% in the PHP group[56]. - The Phase 2 trial for liver-dominant metastatic breast cancer (mBC) is expected to enroll approximately 90 patients, with results anticipated by 2029[64][65]. Regulatory and Compliance - The Centers for Medicare and Medicaid Services established a permanent J-Code for HEPZATO effective April 1, 2024, and granted New Technology Add-on Payment status effective October 1, 2024[71]. - The Company entered into a National Drug Rebate Agreement (NDRA) with CMS on October 23, 2025, which mandates rebates for Medicaid usage and requires pricing submissions to the government[72]. - The company is subject to extensive drug price reporting and payment obligations under the Medicaid Drug Rebate Program (MDRP), which includes submitting Average Manufacturer Price (AMP) and best price data[194]. - The company must also participate in the 340B program, requiring it to charge covered entities no more than the 340B ceiling price for outpatient drugs, calculated based on AMP and rebate amounts[195]. - The company faces potential penalties and sanctions if it fails to comply with reporting obligations under the MDRP and other governmental pricing programs, which could adversely affect its financial condition[194]. - Compliance with FDA regulations includes ongoing recordkeeping, annual product quality reviews, and timely reporting of adverse events[96]. - The FDA may require product recalls or withdraw approvals if the company or its suppliers fail to comply with regulatory requirements[97]. - The company must adhere to strict marketing regulations, including limitations on off-label promotion and the need for FDA approval for product modifications[98]. Financial Performance and Funding - For the year ended December 31, 2025, the company reported a net gain of approximately $2.7 million, while in 2024, it incurred a net loss of $26.4 million[147]. - The company has a substantial accumulated deficit and recurring operating losses, which may exhaust its capital resources and hinder future product commercialization[147]. - The company may require significant additional funding to continue the commercialization of HEPZATO and complete product development projects[151]. - As of December 31, 2025, the company had $43.5 million in cash and cash equivalents and $47.6 million in short-term investments[147]. Supply Chain and Manufacturing - Delcath has sufficient raw materials and components for the HEPZATO KIT to meet anticipated demand and plans to manage supply chain risks through inventory and multiple supplier contracts[26]. - The company is currently reliant on one supplier for melphalan, which poses risks to the supply chain and commercialization efforts[162]. - The company is in discussions with several melphalan NDA holders to mitigate supply interruption risks[165]. - Manufacturing CHEMOSAT and HEPZATO is currently done at the facility in Queensbury, New York, with assembly and packaging operations also established in Galway, Ireland[168]. - The company faces potential delays in obtaining components from third-party suppliers, which could adversely affect the timely delivery of CHEMOSAT and HEPZATO[169]. - Delays in manufacturing may hinder the ability to obtain regulatory approval for other indications in the U.S. and abroad, impacting clinical trial timelines[170]. Competitive Landscape - The healthcare industry is characterized by significant competition, with numerous companies developing alternative treatment methods for liver cancer[131]. - Competition in the cancer treatment industry is intense, with competitors having greater resources and experience, which could impact revenue and profitability[184]. - The company may face challenges in establishing effective sales and marketing capabilities, which are crucial for the commercialization of HEPZATO and other product candidates[177]. Future Plans and Challenges - The company plans to begin studies of HEPZATO for other indications in the future, but delays or failures in clinical trials could negatively impact its business growth[206]. - The company may need to enter into collaborative arrangements for marketing and selling CHEMOSAT and HEPZATO, but success is not guaranteed[180]. - The potential market opportunity for CHEMOSAT and HEPZATO is difficult to estimate, and inaccuracies in assumptions could lead to smaller actual markets than expected[187]. - Legislative changes, such as the ACA and proposed healthcare reforms, could significantly impact drug pricing and market access for the company[110]. - Changes in healthcare laws and regulations, including government restrictions on pricing and reimbursement, may have a material adverse effect on the company's business[201]. - The current administration's policies aimed at reducing drug prices may significantly impact the company's global pricing strategies and profitability[202].